Angiotensin II analogue
- Generic Name
- Angiotensin II analogue
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
Phase 2
Completed
- Conditions
- ThrombocytopeniaLymphopeniaAnemiaNeutropenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Tarix Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00771810
- Locations
- 🇺🇸
USC - LAC Medical Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Southern Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath